Pfizer signs Enodia Therapeutics research and licensing agreement worth more than $500 million for Sec61 protein degradation

Pfizer has entered a research and licensing collaboration with Enodia Therapeutics worth potentially more than $500 million to develop small-molecule therapies targeting protein synthesis through Sec61 inhibition.

Enodia will discover and optimise small-molecule Sec61 inhibitors against multiple collaboration targets using its targeted protein degradation platform, while Pfizer will assume responsibility for subsequent clinical development, manufacturing, regulatory activities and commercialisation.

The agreement includes an upfront payment, research funding, potential development and sales milestones and tiered royalties, positioning the partnership as a substantial investment in a differentiated protein-targeting approach.

Field	Content
Article Type	Deals
Companies	Pfizer; Enodia Therapeutics
Deal Type	Research collaboration and licensing agreement
Potential Deal Value	More than $500 million
Upfront Payment	Included; individual amount not disclosed
Research Funding	Included; amount not disclosed
Milestone Payments	Potential research, development and sales milestones
Royalties	Tiered royalties on future sales
Technology/Modality	Small-molecule Sec61 inhibition and targeted protein degradation
Molecular Target	Sec61 protein translocation complex
Collaboration Scope	Discovery and optimisation of small-molecule Sec61 inhibitors against multiple collaboration targets
Enodia Responsibilities	Research-stage discovery and optimisation of candidate inhibitors
Pfizer Responsibilities	Clinical development, manufacturing, regulatory activities and commercialisation following the research phase
Development Stage	Research and discovery
Therapy Areas	Not specified in the supplied announcement summary
Geography	Global collaboration
What Happened	Pfizer and Enodia Therapeutics signed a research and licensing agreement potentially worth more than $500 million focused on small-molecule Sec61 inhibitors.
Why It Matters	The collaboration provides external validation and substantial potential funding for Enodia's protein-targeting technology while expanding Pfizer's access to differentiated drug discovery approaches.
Supporting Context	Sec61 is involved in protein translocation during synthesis and represents a distinct intervention point for developing therapies against selected protein targets.
Strategic Rationale	Pfizer gains access to Enodia's specialised discovery platform while Enodia benefits from Pfizer's development and commercialisation capabilities.
Potential Impact	Successful research could generate new therapeutic candidates targeting proteins through inhibition of their synthesis and processing.
Key Takeaway	Pfizer has committed to a research and licensing partnership with Enodia carrying potential payments exceeding $500 million.
What to Watch	Disclosure of collaboration targets, research milestones, candidate nominations, development progression and milestone payments.
Primary Source	Enodia Therapeutics
Relevant Date	13 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com